The 2018 AHA/ACC cholesterol guideline recommends add-on lipid-lowering therapy with ezetimibe and/or a PCSK9 inhibitor for adults with very-high ASCVD risk and LDL-C level ≥ 70 mg/dL while taking a maximally tolerated statin dosage [1]. Here, PCSK9 is linked to atherosclerosis.